Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Latest publications, posters & presentations
Global ticker
NASDAQNVAX

SEC

Access filings by selecting the date range and type using the drop-down menus.

NASDAQNVAX
FormDescriptionDateFormat
8-K/AAmendment to a previously filed 8-KMar 14, 2005Open Amendment to a previously filed 8-K in HTML.Open Amendment to a previously filed 8-K in DOC file.Open Amendment to a previously filed 8-K in PDF file.Open Amendment to a previously filed 8-K in XLS file.
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteMar 10, 2005Open A preliminary proxy statement providing notification matters to be brought to a vote in HTML.Open A preliminary proxy statement providing notification matters to be brought to a vote in DOC file.Open A preliminary proxy statement providing notification matters to be brought to a vote in PDF file.Open A preliminary proxy statement providing notification matters to be brought to a vote in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 3, 2005Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 3, 2005Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
1-25      26-50      51-75      76-79
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.